Cartesian Therapeutics Doses First Patient in Phase 2 Clinical Trial of Descartes-08

Cartesian Therapeutics Doses First Patient in Phase 2 Clinical Trial of Descartes-08

By, Admin 5 July 2024

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes-08 to treat systematic lupus erythematosus

Overview

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first patient has been dosed in its phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus (SLE).

About Descartes-08

  • Descartes-08, Cartesian’s lead mRNA cell therapy candidate and a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T), is an autologous mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). 
  • In contrast to conventional DNA-based CAR-T cell therapies, mRNA CAR-T administration is designed not to require preconditioning chemotherapy and is not expected to carry the risk of genomic integration associated with cancerous transformation.
  • Descartes-08 has previously been administered in patients in a phase 2 clinical trial for the treatment of myasthenia gravis (MG). 
  • To date, the safety profile from the MG trial supports outpatient administration with minimal observation.

Words from the CEO: Cartesian

  • Despite recent advances in the SLE treatment landscape, many patients receiving currently available therapies continue to experience severe, incapacitating  asymptomsnd disease progression,” said Carsten Brunn, Ph.D., president and chief executive officer of Cartesian. 
  • Descartes-08 is purposefully designed to overcome the limitations associated with the application of conventional, costly DNA-engineered CAR-T cell therapies for autoimmune diseases. We believe that Descartes-08 could serve as a safe and effective outpatient option for the patients with SLE for whom existing therapies fall short. We are committed to unlocking the full potential of Descartes-08 and look forward to advancing this trial in the months ahead.

Experts on the mRNA CAR-T Cell Therapy

  • Dosing of the first patient with Cartesian’s autologous mRNA CAR-T cell therapy is a monumental accomplishment for the lupus patient community,” said Susan Manzi, Chair of the Medicine Institute at Allegheny Health Network and Medical Director for the Lupus Foundation of America. 
  • Treatment options for lupus patients are suboptimal. I am hopeful that Descartes-08 administered as an outpatient therapy will demonstrate early and long-lasting clinical benefit in patients with certain B cell-mediated autoimmune diseases like lupus.

Phase 2 Open-Label Trial

The phase 2 open-label trial (NCT06038474), which is expected to enroll up to 30 adult patients, is designed to evaluate the safety and tolerability of outpatient administration of Descartes-08 without preconditioning chemotherapy for the treatment of patients with moderate or severe SLE refractory to immunosuppressant therapy. Secondary outcome measures will assess overall disease activity.

About Systemic Lupus Erythematosus

  • Systemic lupus erythematosus is an incurable chronic autoimmune disease marked by systemic inflammation that affects multiple organ systems including the skin, joints, kidneys, brain, and heart. 
  • The symptoms of SLE can range from mild to life-threatening and often include fatigue, joint pain, rash, and fever. 
  • SLE impacts approximately 1.5 million people in the United States.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!